|Healthcare review: Rosetta Genomics, Rockwell Medical, InterMune, Hansen Medical, Nektar Therapeutics Are Notable Movers|
|By Staff and Wire Reports|
|Friday, 23 November 2012 12:44|
Market participants were also encouraged by signs of progress in talks about releasing aid to debt-saddled Greece, and piled into U.S. retail shares as the holiday shopping season got underway.
Following are the notable movers at mid day on Friday:
Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) shares climbed 11.84% to $4.77 in the early hour. The company’s third quarter sales increased 6% to $12.7 million, as compared to third quarter 2011. Gross profit increased 19.6% or $0.3 million over third quarter of 2011. Net loss was ($17.9) million compared to ($5.0) million in third quarter of 2011 primarily due to higher R&D expense.
Rockwell Medical Inc. (NASDAQ:RMTI) shares jumped 11.64% to $7.16. The company issued its quarterly earnings data recently. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.36. The company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.57 million.
InterMune, Inc. (NASDAQ:ITMN) stock gained 6.47% to $9.22. The company reported third-quarter net loss of $45.4 million or $0.70 per share, compared to $38.2 million or $0.63 per share in the same quarter last year. Analysts expected a loss of $0.84 per share. Total revenues for the quarter rose to $7.5 million from $0.1 million last year. Analysts estimated revenues of $6.16 million
Hansen Medical, Inc. (NASDAQ:HNSN) stock increased 4.65% to $2.25. The company is scheduled to present at the 24th Annual Piper Jaffray Healthcare Conference. The conference is being held November 27-28, 2012, at the New York Palace Hotel, in New York, NY. Hansen Medical is scheduled to present on Wednesday, November 28, 2012 at 2:30 p.m. Eastern Time.
Nektar Therapeutics (NASDAQ:NKTR) shares fell 3.94% to $6.10 in the early hour. The FDA raised concerns that a class of opioid constipation medications may cause heart problems. The company said that the FDA's heart-safety concerns could cast new risks and uncertainties over the development of its constipation medication known as naloxegol or NKTR-118.